What are the Amanta Healthcare IPO dates?

The IPO opens on 1 September 2025 and closes on 3 September 2025.

What is the price band and lot size?

The price band is ₹120–₹126 per share and the minimum lot size is 119 shares (₹14,280 at the lower band).

What is the Amanta Healthcare IPO issue size?

₹126 crore (100% fresh issue as per RHP/filings).

What does Amanta Healthcare do?

It manufactures sterile IV fluids and small-volume parenterals under brands like SteriPort, serving hospitals, institutions and tenders.

Amanta Healthcare IPO Review 2025: Dates, Price Band, Lot Size, GMP, Financials & Recommendation

Amanta Healthcare IPO (2025) — Dates, Price Band, Lot Size, GMP, Financials & Verdict

Premium IPO Research — NiveshGuruji

🚀 Apply Smartly with the Right Tools

Open a FREE Angel One Demat, track allotment, and get real-time IPO alerts:

💳 Open FREE Demat (Angel One) 📲 Download IPOFocus App 📢 Join Telegram (Daily Updates)

Note: Investing in IPOs involves risks. Read the RHP before applying.

1) Basic IPO Details

Item	Details
Company	Amanta Healthcare Limited Pharma — IV Fluids & SVP
IPO Open / Close	1 Sep 2025 to 3 Sep 2025 (Mon–Wed)
Listing Date (T+6)	9 Sep 2025 (tentative)
Price Band	₹120 – ₹126 per share
Lot Size (Retail)	119 shares (min investment ≈ ₹14,280 at ₹120)
Issue Size	₹126 crore
Type of Issue	Fresh Issue
Lead Manager	Beeline Capital Advisors
Registrar	As per RHP; check bid platform on opening day for final

Source: Exchange filing/RHP & IPO trackers. Dates/terms as per public disclosures; verify on the day of bidding.

💡 Quick Apply Tip

Use UPI for faster retail bids. Prefer cut-off price in high-demand issues.

Open Angel One (Free) Download IPOFocus Join Telegram

2) Company Profile

Business: Amanta manufactures sterile IV fluids (normal saline, dextrose, RL, etc.) and small-volume parenterals (SVP), supplying to hospitals, institutions and tenders. Capacity additions and product breadth are the core growth drivers.

Promoters & Positioning: Backed by experienced promoters with focus on quality systems for sterile products. The company operates in a relatively defensive healthcare subsegment where demand is linked to hospitalisation and procedures.

Competitors: Listed peers in IV fluids include Denis Chem Lab (peer shown in RHP). Competition is based on tender wins, cost efficiency and capacity.

RHP peer table references Denis Chem Lab for FY24 comparison.

3) Utilisation of Funds (Objects of the Issue)

Capex — SteriPort line (Hariyala, Gujarat): ₹70.0 cr from proceeds
Capex — New SVP line (Hariyala, Gujarat): ₹30.13 cr from proceeds
General Corporate Purposes: Balance (within regulatory limit)

Why it matters: Capex into sterile lines can drive volume growth and operating leverage. GCP should remain ≤25% of gross proceeds as per regulations.

As per RHP, deployment planned across FY26–FY27.

4) Financial Performance (₹ Cr)

Year	Total Income	Revenue from Ops	PAT	EPS (₹)
FY23	₹262.70	₹259.13	₹–21.11	–0.79
FY24	₹281.61	₹280.34	₹3.63	1.35
FY25	₹276.09	₹274.71	₹105.01	3.71

Trend: FY25 shows a sharp PAT recovery, with stable topline vs FY24. EPS improved to ₹3.71 in FY25 (restated).

Figures are restated (₹ lakhs in RHP; converted here to ₹ Cr for readability). EPS based on weighted average shares as per RHP.

5) Valuation Snapshot

At the upper band (₹126), implied P/E will depend on post-issue shares. Using FY25 EPS of ₹3.71 (restated), the pre-issue P/E proxy ≈ 34x. Post-issue dilution will adjust EPS. Compare against peers and growth visibility.

ROE (FY25): ~10.9% (restated)
Debt/Equity: Refer RHP schedules; manageable leverage is preferred in capex upcycles.
P/B: To be inferred on listing/offer valuation vs net worth.

These are directional checks. Use final basis of pricing and post-issue capital for precise multiples.

6) Peer Comparison (FY24)

Company	Total Income	Revenue (Ops)	Remarks
Amanta Healthcare	₹281.61 Cr	₹280.34 Cr	Recovery phase; capex driven expansion
Denis Chem Lab	₹169.21 Cr	₹167.82 Cr	Listed peer cited in RHP

Peer set is indicative. Broader listed pharma/IV fluid names may have different product mixes and margin profiles.

7) Shareholding Pattern (Post-IPO)

Exact post-issue shareholding will be finalised after pricing and allotment. Generally, higher promoter holding post-issue signals confidence; track final numbers in the Prospectus.

8) Grey Market Premium (GMP)

Unofficial market chatter indicates a positive GMP around recent sessions. GMP is unofficial & volatile and should not be the sole basis for investment.

📌 Reminder: GMP can change rapidly; rely on fundamentals & allocation data rather than GMP alone.

9) Market/Analyst Views

Media & brokerage commentary highlights: defensive healthcare demand, capacity-led growth, tender exposure risks.
Watch for final pricing, anchor book quality, and subscription across QIB/HNI/Retail.

Track subscription data during the 1–3 Sep window and anchor participation (T-1) for better conviction.

10) Final Recommendation

Short Term (Listing): Moderately positive bias if subscription is strong across QIB/HNI and pricing remains reasonable. Hospital/IV consumption is steady; tender wins are key near-term swing factor.

Long Term (Investment): Cautious Positive — capex into sterile lines can support growth; monitor execution, working capital, and margin trajectory post expansion.

Analyst Note: FY25 profitability recovered well. Valuation comfort vs peers and order/tender visibility will determine the medium-term rerating. Conservative investors may wait for listing & Q2 results before larger allocation.